Cannabidiol
EPIDIOLEX
What it isCannabinoid modulating several non-CB1 targets; Dravet, Lennox-Gastaut, and tuberous-sclerosis seizures.
Why this oneIt provides a standardized prescription product for epilepsies often self-treated with unregulated cannabis extracts.
What limits itHepatotoxicity is amplified by valproate; monitor liver tests. It raises exposure to clobazam’s active metabolite.
FDA-approved for
- Dravet/Lennox-Gastaut/TSC seizures (2018)
Off-label
- anxiety (limited evidence)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Oral CBD (per product directions; no specific indication stated) | Adults & children ≥12 yr | 1–3 capsules | 400 mg CBD/day (20 capsules) |
Renal Undefined
Hepatic Undefined
Do not exceed 400 mg CBD (20 capsules) daily
Instructions
- Take with a glass of water; repeat if required
- Use regularly for at least 4–12 weeks for full effect
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskHepatotoxicity, especially with valproate
Cost, est. cash$300–$2,500/month
Generic entry2041 est.
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.
Mechanism of action: Cannabidiol ballicule
Open Cannabidiol in the interactive console ↗
Memory aids: mascots and interaction avatars
